Moorin, Rachael E <br/><br/>
Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy.  [electronic resource] 

 -  Nuclear medicine communications  Apr 2007 
 - 261-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0143-3636 
<br/><br/><label>Standard No.: </label>10.1097/MNM.0b013e328014a11e  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Body Burden<br/>Chelating Agents--administration & dosage<br/>Drug Evaluation, Preclinical<br/>Kidney--metabolism<br/>Kidney Diseases--etiology<br/>Male<br/>Metabolic Clearance Rate--drug effects<br/>Neuroectodermal Tumors--metabolism<br/>Octreotide--administration & dosage<br/>Organ Specificity<br/>Peptides--administration & dosage<br/>Radiation Dosage<br/>Radiation Injuries--etiology<br/>Radiation-Protective Agents--administration & dosage<br/>Radiopharmaceuticals--administration & dosage<br/>Rats<br/>Rats, Wistar<br/>Succimer--administration & dosage<br/>Treatment Outcome